References
1. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective.Cancer Cell. 2002;2(6):437-445.
2. Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies
for Philadelphia chromosome-like acute lymphoblastic leukemia.Blood Adv. 2020;4(1):218-228.
3. Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses
of Ph-like ALL in NCI standard-risk patients: a report from the
Children’s Oncology Group. Blood. 2018;132(8):815-824.
4. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating
lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med.2014;371(11):1005-1015.
5. McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders.Nat Rev Dis Primers. 2021;7(1):73.
6. Castro EC, Blazquez C, Boyd J, et al. Clinicopathologic features of
histiocytic lesions following ALL, with a review of the literature.Pediatr Dev Pathol. 2010;13(3):225-237.
7. Fenu EM, Margolskee E, Pillai V. Transdifferentiation of
B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.Am J Hematol. 2023;98(8):E216-E218.
8. Kato M, Seki M, Yoshida K, et al. Genomic analysis of clonal origin
of Langerhans cell histiocytosis following acute lymphoblastic
leukaemia. Br J Haematol. 2016;175(1):169-172.
9. Pawinska-Wa Sikowska K, Cwiklinska M, Wyrobek E, et al. Disseminated
Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis
Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report.Front Oncol. 2020;10:921.
10. Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES.
Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal
origin. Lancet Oncol. 2004;5(4):248-250.
11. Newman H, MacFarland SP, Brodeur GM, et al. B-cell acute
lymphoblastic leukemia and juvenile xanthogranuloma in a patient with
ETV6 thrombocytopenia and leukemia predisposition syndrome: novel
clinical presentation and perspective. Haematologica. 2023.
12. Salzer WL, Burke MJ, Devidas M, et al. Toxicity associated with
intensive postinduction therapy incorporating clofarabine in the very
high-risk stratum of patients with newly diagnosed high-risk
B-lymphoblastic leukemia: A report from the Children’s Oncology Group
study AALL1131. Cancer. 2018;124(6):1150-1159.
13. Aparicio G, Mollet J, Bartralot R, et al. Eruptive juvenile
xanthogranuloma associated with relapsing acute lymphoblastic leukemia.Pediatr Dermatol. 2008;25(4):487-488.
14. Bailey KM, Castle VP, Hummel JM, Piert M, Moyer J, McAllister-Lucas
LM. Thalidomide therapy for aggressive histiocytic lesions in the
pediatric population. J Pediatr Hematol Oncol.2012;34(6):480-483.
15. Cheon E, Yang S, Han JH, Lee KC, Park JE. Systemic Juvenile
Xanthogranuloma Involving the Bone Marrow, Multiple Bones, and the Skin
That Developed During Treatment of Acute Lymphoblastic Leukemia in
Remission State. Pediatr Dev Pathol. 2018;21(5):489-493.
16. Perez-Becker R, Szczepanowski M, Leuschner I, et al. An aggressive
systemic juvenile xanthogranuloma clonally related to a preceding T-cell
acute lymphoblastic leukemia. Pediatr Blood Cancer.2011;56(5):859-862.
17. Rotte JJ, de Vaan GA, Koopman RJ. Juvenile xanthogranuloma and acute
leukemia: a case report. Med Pediatr Oncol. 1994;23(1):57-59.
18. Morier P, Merot Y, Paccaud D, Beck D, Frenk E. Juvenile chronic
granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis.
Case report and review of the literature. J Am Acad Dermatol.1990;22(5 Pt 2):962-965.
19. Paxton CN, O’Malley DP, Bellizzi AM, et al. Genetic evaluation of
juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary
lesions, advanced cases may show more complexity. Mod Pathol.2017;30(9):1234-1240.
20. Egan C, Lack J, Skarshaug S, et al. The mutational landscape of
histiocytic sarcoma associated with lymphoid malignancy. Mod
Pathol. 2021;34(2):336-347.
21. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are
prevalent in relapsed childhood acute lymphoblastic leukemia and confer
sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430.
22. Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship
between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell
histiocytosis. Lancet Oncol. 2005;6(6):435-437.